Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian, Aaron Elliott Lisberg, Krikor Bornazyan et al. · The Lancet Oncology · 2017
Cited by 1,089 works. doi:10.1016/s1470-2045(17)30380-7
Authors
- Narek Shaverdian
- Aaron Elliott Lisberg
- Krikor Bornazyan
- Darlene Veruttipong
- Jonathan Wade Goldman
- Silvia Chiara Formenti
- Edward B. Garon
- Percy P. Lee
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Cancer statistics, 2016
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Checking the Cox model with cumulative sums of martingale-based residuals
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer